Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 20 May 2022, 11:10 HKT/SGT
Share:
    

Source: Sirnaomics Ltd.
Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit

Gaithersburg, MD, USA and Suzhou BioBay, China, May 20, 2022 - (ACN Newswire) - Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company's Executive Director and Chief Medical Officer, Dr. Michael Molyneaux, will present clinical study results of its leading product candidate STP705 for the treatment of non-melanoma skin cancers, and the Company's clinical development strategy based on its strong presence in both the U.S. and China, at the 2022 Pre-ASCO (American Society of Clinical Oncology) China Summit, entitled: "RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers" in a session of Development and Regulatory Strategy for the U.S. and China, on May 21, 2022 with a live Zoom Webinar. Further details about the presentation are listed below.

Based on its dual-targeted siRNA therapeutics design and polypeptide nanoparticle delivery technology, Sirnaomics has established an enriched product pipeline of RNAi therapeutics for treatment of various types of cancer conditions, including the first successful demonstration of a Phase IIa clinical validation of STP705 for treatment of skin squamous cell carcinoma in situ, followed by clinical Phase I study of STP707 for multiple solid tumors such as liver cancers. Additionally, the Company intends to file INDs to initiate clinical studies in 2023 for three programs currently in later preclinical stage: STP355 for colorectal cancer and melanoma, STP369 for head and neck cancer and bladder cancer, and STP779 for cholangiocarcinoma. The development of all these novel RNAi therapeutic programs has taken advantage of the Company's well positioning in both the U.S. and China.

Event:
2022 Pre-ASCO China Summit #3: Development and Regulatory Strategy for US & China

Presentation:
RNAi Therapeutics in Oncology, from Skin Cancers to Liver Cancers

Presenter:
Sirnaomics Chief Medical Officer Michael Molyneaux

Dates/Times:
May 21 (Saturday), 2022, Beijing Time (9:20 a.m.); May 20 (Friday), 2022, EST (9:20 p.m.), PST (6:20 p.m.).

Venue:
Live Zoom Webinar https://lm.enewie.com/live/WULICB

Language:
English with Chinese simultaneous translation

"Presenting Sirnaomics' clinical results and development strategy in oncology at this unique forum represents advancement of the Company's cancer RNAi therapeutics programs with strong positioning in both the U.S. and China. The therapeutic areas of focus for skin cancers and liver cancers demonstrated the Company's overarching intention for addressing unmet clinical needs of the two patient populations in the two countries". Comments from Dr. Patrick Lu, Founder, Chairman of the Board, Executive Director, President and CEO of Sirnaomics, "The 2022 Pre-ASCO China Summit provides an excellent platform to discuss Development and Regulatory Strategy for the U.S. & China".

About Michael Molyneaux, MD, MBA
Dr. Molyneaux is a board-certified physician in both Canada and the United States. He has been the Chief Medical Officer at Sirnaomics (2257.HK) since 2015. Dr. Molyneaux is currently responsible for Medical Affairs, Clinical Operations, and Regulatory Affairs activity within the Company and has led clinical activities for IND filings in multiple therapeutic areas including fibrosis and oncology as well as leading the efforts for three orphan drug designations for STP705 under US FDA. He has practiced clinical medicine since 1998 having received his Medical Doctorate from Dalhousie University and he began doing clinical trial research in 2005 and was a Principal Investigator for Phase 2 and 3 studies working with companies such as Shire, Pfizer, Smith & Nephew, GSK, and AstraZeneca. He completed his MBA at Olin School of Business at Washington University in St. Louis Missouri in 2012. He is currently a Diplomate with the American Board of Family Medicine and a Fellow of the Canadian College of Family Physicians and a Licensed Physician in good standing in the state of California.

About Sirnaomics
Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the United States, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics for its core product, STP705. Learn more at www.sirnaomics.com.

CONTACT:
Michael Molyneaux, MD, MBA
Executive Director and Chief Medical Officer, Sirnaomics
Email: MichaelMolyneaux@sirnaomics.com

Investor Relations:
Nigel Yip
Chief Financial Officer, China, Sirnaomics
Email: NigelYip@sirnaomics.com

US Media Contact:
Alexis Feinberg
Tel: +1 203 939 2225
Email: Alexis.Feinberg@westwicke.com

Asia Media Contact:
Bunny Lee
Tel: +852 3150 6707
Email: sirnaomics.hk@pordahavas.com



Topic: Press release summary
Source: Sirnaomics Ltd.

Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Sirnaomics Ltd.
June 21, 2022 23:45 HKT/SGT
Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead(TM) Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
June 16, 2022 11:42 HKT/SGT
Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
May 30, 2022 15:38 HKT/SGT
Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
May 11, 2022 14:33 HKT/SGT
Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead(TM) Programs at the TIDES USA 2022
Dec 30, 2021 15:55 HKT/SGT
Sirnaomics Ltd., RNA Therapeutics Biopharmaceutical Company with Presence in China and US, Lists on Main Board of SEHK
Dec 19, 2021 20:48 HKT/SGT
Sirnaomics Ltd. Announces Proposed Listing on the Main Board of SEHK
More news >>
 News Alerts
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: